Author

Brendan D. Parent

Dana-Farber Cancer InstituteORCID 0009-0001-8258-1755Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 1 Organism:human· 1 Approach:machine learning (classical)· 1 Assay:protein structure· 1 Assay:proteomics· 1

Frequent Co-Authors

Andrew J. AguirreiD· 2 shared Aparna PadhyeiD· 1 shared Bin Zou· 1 shared Bryan K. S. YeungiD· 1 shared Chan Johng KimiD· 1 shared Clint A. StalneckeriD· 1 shared David A. BakeriD· 1 shared David H. PengiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Andrew J. AguirreORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintOct 2, 2026

KRAS inhibition drives adaptive surfaceome remodeling and reveals ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer

Jonathan M. DeLiberty, Fan Yi Kong, Qijia Yu…·Joseph Douglas Mancias

This study identifies ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer by analyzing proteomic changes induced by KRAS inhibition and developing an antibody drug conjugate.

DOI 10.64898/2026.10.01.756025

humanproteomics

𝕏 PostBluesky

BioengineeringbioRxivPreprintSep 22, 2026

De novo design of protease-activatable cytokine prodrugs

Hojeong Shin, Julissa G. Tello, Chan Johng Kim…·David A. Baker

This study designs protease-activatable cytokine prodrugs to reduce toxicity while maintaining antitumor efficacy in tumor models.

DOI 10.64898/2026.09.19.752834

protein structureexperimental assay

𝕏 PostBluesky